|
Nov 5
|
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
|
|
Nov 4
|
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
|
|
Nov 1
|
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
|
|
Oct 14
|
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
|
|
Sep 3
|
Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug
|
|
Sep 3
|
Arrowhead to file NDA after pivotal rare disease trial meets all endpoints
|
|
Sep 2
|
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
|
|
Apr 26
|
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
|
|
Apr 24
|
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
|
|
Apr 24
|
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
|